- $14.65m
- $25.33m
Annual cashflow statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.6 | -16.4 | -23.2 | -50.3 | -65 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.42 | 0.388 | 1.89 | 6.31 | 22.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.45 | 0.47 | -11.2 | 3.24 | 10.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -14 | -13.3 | -30.1 | -37.5 | -30.4 |
| Capital Expenditures | -0.99 | -1.15 | -5.16 | -11.6 | -6.43 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -21.3 | 6.5 | 13.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.99 | -1.15 | -26.5 | -5.13 | 7.01 |
| Financing Cash Flow Items | 2.3 | -2.17 | 0.836 | -0.372 | -0.061 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.45 | 65.2 | 78.8 | -6.13 | 2.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.5 | 50.7 | 22.3 | -48.7 | -21.1 |